Efficacy, safety, and pharmacokinetics by BMI category in Phase 3/3b cabotegravir + rilpivirine long-acting trials.
Elliot E, Polli JW, Patel P, Garside L, Grove R, Barnett V, Roberts J, Byrapuneni S, Crauwels H, Ford SL, Van Solingen-Ristea R, Birmingham E, D'Amico R, Baugh B, van Wyk J.
Elliot E, et al. Among authors: grove r.
J Infect Dis. 2023 Dec 22:jiad580. doi: 10.1093/infdis/jiad580. Online ahead of print.
J Infect Dis. 2023.
PMID: 38134313